Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.
Dalens L, Niogret J, Richard C, Chevrier S, Foucher P, Coudert B, Lagrange A, Favier L, Westeel V, Kim S, Adotevi O, Chapusot C, Martin L, Arnould L, Kaderbhai CG, Boidot R.
Dalens L, et al. Among authors: chevrier s.
Mol Cancer. 2023 Jul 29;22(1):120. doi: 10.1186/s12943-023-01829-4.
Mol Cancer. 2023.
PMID: 37516818
Free PMC article.